The Epstein-Barr virus remains linked to a spectrum of severe conditions, including various lymphoproliferative disorders, autoimmune complications, and risks for transplant patients. Despite the clinical burden, therapeutic options for these patients have historically remained restricted. Innovative Molecules intends to fill this gap by leveraging its expertise in targeted antiviral therapeutics, building upon the momentum of its existing pipeline.
Innovative Molecules Targets Epstein-Barr Virus with New Antiviral Program
Munich-based clinical-stage biotech Innovative Molecules is expanding its focus on herpesvirus-mediated diseases, announcing a new antiviral program aimed at the Epstein-Barr virus. The company plans to move its novel, potent polymerase inhibitors into Phase 1 clinical trials by 2027 to address currently underserved patient populations.
CEO Florian Vogel noted that the expansion reflects a commitment to tackling high-value indications where conventional treatments fall short. This new program joins the company’s lead asset, adibelivir (IM-250), which is currently under development to treat Herpes simplex virus infections. By diversifying its portfolio, the firm aims to secure a stronger position in the broader landscape of herpesvirus-associated care.
Comments (0)
No comments yet. Be the first!